• Warburg Pincus-led investor group agreed to buy a controlling stake in PANTHERx Rare from Nautic Partners, General Atlantic, The Vistria Group.
• Nautic Partners and PANTHERx management will remain significant shareholders.
• Deal targets continued investment in the rare disease pharmacy platform while keeping PANTHERx independent and patient-first.
• Closing expected in the coming months, subject to customary conditions and approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Warburg Pincus LLC published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.